Affordability - The forgotten criterion in health-care priority setting

Health Economics

Volumn 18, Issue 4, 2009, Pages 373-375

  Cleary, Susan M ^a   Mcintyre, Di ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMIC EVALUATION; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; RESOURCE ALLOCATION;

AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; COST-BENEFIT ANALYSIS; FINANCING, PERSONAL; HEALTH PRIORITIES; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; SOUTH AFRICA;

EID: 67149126583     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1450     Document Type: Editorial

References (14)

1. Badri M, Cleary S et al. 2006. When to initiate HAART in sub-Saharan Africa? A South African cost-effectiveness study. Antiviral Therapy 11:63-72.
2. Birch S, Donaldson C. 1987. Applications of cost-benefit analysis to health care - departures from welfare economic theory. Journal of Health Economics 6:211-225.
3. Birch S, Gafni A. 1992. Cost-effectiveness/utility analyses. Do current decision rules lead us to where we want to be? Journal of Health Economics 11:279-296.
4. Birch S, Gafni A. 2006. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the costeffectiveness threshold. Journal of Health Service and Research Policy 11(1):46-51.
5. Cleary S, McIntyre D et al. 2006. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Effectiveness and Resource Allocation 4:20.
6. Cleary S, Mooney G et al. 2008. Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting. Under review in Health Economics.
7. Donaldson C. 1998. The (Near) equivalence of cost-effectiveness and cost-benefit analyses. Pharmacoeconomics 13(4):386-396.
8. Donaldson C, Currie G et al. 2002. Cost-effectiveness analysis: contra-indications. British Medical Journal 325:891-894.
9. Drummond M, Jefferson T. 1996. Guidelines for authors and peer reveiwers of economic submissions to the BMJ. British Medical Journal 313:275-283.
10. HIV and AIDS and STI National Strategic Plan 2007-2011. 2007. Pretoria, South African National AIDS Council (SANAC): 1-136.
11. Loubiere S, Marhoum El Filal K et al. 2008. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience. Antiviral Therapy 13(2):241-251.
12. UNAIDS 2007. AIDS epidemic update: December 2007, Joint United Nations Programme on HIV/AIDS and World Health Organisation.
13. WHO and UNAIDS 2004. Consultation on ethics and equitable access to treatment and care for HIV/AIDS. Geneva, World Health Organisation/Joint United Nations Programme on HIV/AIDS.
14. Yazdanpanah Y, Losina E et al. 2005. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/ AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 19(12):1299-1308.